Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Zheng, Chunning ^a   Jia, Wei ^b   Tang, Yong ^b   Zhao, Huiliang ^b   Jiang, Yingsheng ^a   Sun, Shaochuan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Mesothelin; P53; Pancreatic cancer; Proliferation, apoptosis

Indexed keywords

CASPASE 3; MESOTHELIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PUMA PROTEIN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GPI-LINKED PROTEINS; HUMANS; MICE; MICE, NUDE; MUTATION; PANCREATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866883382     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-84     Document Type: Article

References (35)

1. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S, Oncology 2011 81 259 272 10.1159/000334449 22116519
2. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, Pastan I, Proc Natl Acad Sci USA 1996 93 136 140 10.1073/pnas.93.1.136 8552591 (Pubitemid 26041483)
3. Mesothelin is not required for normal mouse development or reproduction. Bera TK, Pastan I, Mol Cell Biol 2000 20 2902 2906 10.1128/MCB.20.8.2902-2906. 2000 10733593 (Pubitemid 30183509)
4. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Ordonez NG, Mod Pathol 2003 16 192 197 10.1097/01.MP.0000056981.16578.C3 12640097 (Pubitemid 36337423)
5. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Hassan R, Laszik ZG, Lerner M, Raffield M, Postier R, Brackett D, Am J Clin Pathol 2005 124 838 845 10.1309/F1B64CL7H8VJKEAF 16416732 (Pubitemid 41740183)
6. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas. Identification of a new pancreataic cancer marker by serial analysis of gene expression (SAGE). Clin. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Cancer Res 2001 7 3862 3868 (Pubitemid 34044602)
7. Localization of mesothelin in epithelial ovarian cancer. Hassan R, Kreitman RJ, Pastan I, Willingham MC, Appl Immunohistochem Mol Morphol 2005 13 243 247 10.1097/01.pai.00000141545.36485.d6 16082249 (Pubitemid 41209017)
8. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types. Miettinen M, Sarlomo-Rikala M, Am J Surg Pathol 2003 27 150 158 10.1097/00000478-200302000-00002 12548160 (Pubitemid 36152223)
9. Application of mesothelin immunostaining in tumor diagnosis. Ordonez NG, Am J Surg Pathol 2003 27 1418 1428 10.1097/00000478-200311000-00003 14576474 (Pubitemid 37315193)
10. Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cheng WF, Hung CF, Chai CY, Chen CA, Lee CN, Su YN, Tseng WY, Hsieh CY, Shih Ie M, Wang TL, Wu TC, Cancer 2007 110 420 431 10.1002/cncr.22781 17559144 (Pubitemid 47121904)
11. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q, Mol Cancer Ther 2008 7 286 296 10.1158/1535-7163.MCT-07-0483 18281514 (Pubitemid 351302523)
12. TSC2 gene mutant (Eker) rat model of a Mendelian dominantly inherited cancer. Hino O, Fukuda T, Satake N, et al. Prog Exp Tumor Res 1999 35 95 108 10377754
13. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. Prieve MG, Moon RT, BMC Dev Biol 2003 3 2 10.1186/1471-213X-3-2 12697065
14. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O, Biochem Biophys Res Commun 2000 275 134 140 10.1006/bbrc.2000.3280 10944454 (Pubitemid 30663642)
15. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q, Carcinogenesis 2011 32 1013 1024 10.1093/carcin/bgr075 21515913
16. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Bharadwaj U, Li M, Chen C, Yao Q, Mol Cancer Res 2008 6 1755 1765 10.1158/1541-7786.MCR-08-0095 19010822
17. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q, Mol Cancer 2011 10 106 10.1186/1476-4598-10-106 21880146
18. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K, Clin Cancer Res 2006 12 4983 4988 10.1158/1078-0432.CCR-06-0441 16914588 (Pubitemid 44338587)
19. Yee KS, Vousden KH, Carcinogenesis 2005 26 1317 1322 10.1093/carcin/ bgi122 15888490 (Pubitemid 41430092)
20. PUMA, a potent killer with or without p53. Yu J, Zhang L, Oncogene 2008 27 Suppl 1 71 S83 19641508
21. Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma. Zheng W, Jian Z, Jia F, Shuang-Jian Q, Yao Y, Xiao-Wu Huang Z-YT, Clin Cancer Res 2008 14 5124 10.1158/1078-0432.CCR-07-4774 18698030
22. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Chang K, Pastan I, Willingham MC, Int J Cancer 1992 50 373 381 10.1002/ijc.2910500308 1735605
23. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A, J Biol Chem 2004 279 9190 9198 10.1074/jbc.M312372200 14676194 (Pubitemid 38295982)
24. Control of human mesothelinexpressing tumors by DNA vaccines. Chang CL, Wu TC, Hung CF, Gene Ther 2007 14 1189 1198 10.1038/sj.gt.3302974 17581599 (Pubitemid 47215422)
25. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA, Anticancer Res 2006 26 4721 4728 17214332
26. Suppression of human colorectal carcinoma cell growth by wild type p53. Baker SJ, Markowitz S, Fearton ER, WilIson JKU, Vogelstemn B, Science (Washington DC) 1990 249 912 915 10.1126/science.2144057
27. Negative growth regulation in a glioblastoma cell line that conditionally expresses human wild-type p53. Mercer WE, Shields MT, Amin M, Sauve MGJ, Appella E, Romano JW, UlIrich SJ, Proc NatI Aced Sd USA 1990 87 6166 6170 10.1073/pnas.87.16.6166 (Pubitemid 20258977)
28. p53 functions as a cell cycle control protein in osteosarcomas. DilIer L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker S, Vogelstemn B, Friend SH, Mol Cell Biol 1990 10 5772 5781 2233717
29. Genetic mechanisms of tumor suppression by the human p53 gene. Chen PL, Chen Y, Bookstein R, Lee WH, Science (Washington DC) 1990 250 1576 1579 10.1126/science.2274789
30. PUMA induces the rapid apoptosis of colorectal cancer cells. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B, Mol Cell 2001 7 673 682 10.1016/S1097-2765(01)00213-1 11463391 (Pubitemid 32706358)
31. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L, Proc Natl Acad Sci USA 2003 100 1931 1936 10.1073/pnas.2627984100 12574499 (Pubitemid 36254551)
32. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI, Nature 2006 443 214 217 10.1038/nature05077 16957739 (Pubitemid 44387609)
33. Sp1 and p73 activate PUMA following serum starvation. Ming L, Sakaida T, Yue W, Jha A, Zhang L, Yu J, Carcinogenesis 2008 29 1878 1884 10.1093/carcin/bgn150 18579560
34. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, et al. J Biol Chem 2004 279 8076 8083 14634023 (Pubitemid 38294697)
35. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, et al. Cell 2005 123 641 653 10.1016/j.cell.2005.09.029 16286009 (Pubitemid 41613746)